top of page
Biosciences
Offspring
Insights & Updates
De-Risking Synucleinopathy Therapeutics: A Human Tissue-First Framework for Target Validation
The transition from preclinical promise to clinical efficacy, the so-called "Translational Gap", remains the most perilous stage of drug development. Nowhere is this chasm wider than in neurodegeneration, where billions of dollars and years of research are lost when promising candidates fail in late-stage trials. The fundamental reason is often a stark divergence between the simplified environments of preclinical models and the complex, heterogeneous reality of human disease.
Featured
Search
Offspring assist AstraZeneca with diabetes project aimed to validate a potential novel biomarker
In a recently published study in Plos One, a research team led by Dr Sara Hansson at AstraZeneca presented data which demonstrate that secretagogin, an intracellular calcium-binding intracellular protein highly enriched in pancreatic islets, may serve as biomarker in the blood for beta cell dysfunction in individuals with type 2 diabetes Offspring supported this project by performing multiplexed immunofluorescence-based detection of secretagogin selectively within the insulin
-
Sep 16, 20212 min read
Offspring supports MedImmune in a study published in Diabetes
In a recently published study by a research team from MedImmune led by Dr. Arun Sharma, novel data was presented which shows that in vivo treatment with a combination of the neurotrophic factor neuturin (NRTN) and liraglutide in hyperglycemic ZDF rats synergistically improved glycemic control and enhanced metabolic parameters as compared to liraglutide alone, highlighting the potential of novel combinatorial approaches to prevent or reverse diabetes progression Offspring are
-
Sep 16, 20211 min read
bottom of page